Current Progress of Virus-mimicking Nanocarriers for Drug Delivery
暂无分享,去创建一个
[1] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[2] S. Kuroda,et al. Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. , 2015, Advanced drug delivery reviews.
[3] Mark A. Kay,et al. Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.
[4] C. Sureau,et al. Role of the Antigenic Loop of the Hepatitis B Virus Envelope Proteins in Infectivity of Hepatitis Delta Virus , 2005, Journal of Virology.
[5] S. Kuroda,et al. Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. , 1992, The Journal of biological chemistry.
[6] Ivan R. Nabi,et al. Caveolae/raft-dependent endocytosis , 2003, The Journal of cell biology.
[7] P. Stewart,et al. Role of αv Integrins in Adenovirus Cell Entry and Gene Delivery , 1999, Microbiology and Molecular Biology Reviews.
[8] P. Bolhuis,et al. Self-assembly of microcapsules via colloidal bond hybridization and anisotropy , 2015, Nature.
[9] P. Stewart,et al. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. , 1999, Microbiology and molecular biology reviews : MMBR.
[10] Harvey T. McMahon,et al. Molecular mechanism and physiological functions of clathrin-mediated endocytosis , 2011, Nature Reviews Molecular Cell Biology.
[11] L. Pelkmans,et al. Ameobal Pathogen Mimivirus Infects Macrophages through Phagocytosis , 2008, PLoS pathogens.
[12] John J Rossi,et al. RNAi and small interfering RNAs in human disease therapeutic applications. , 2010, Trends in biotechnology.
[13] Ari Helenius,et al. Virus entry by macropinocytosis , 2009, Nature Cell Biology.
[14] Y. Kaneda,et al. Increased expression of DNA cointroduced with nuclear protein in adult rat liver , 1995, Journal of Molecular Medicine.
[15] J. Ott,et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.
[16] I. Rodrı́guez-Crespo,et al. Prediction of a putative fusion peptide in the S protein of hepatitis B virus. , 1994, The Journal of general virology.
[17] P. Spear,et al. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. , 2001, The Journal of clinical investigation.
[18] G. Nemerow,et al. Adenovirus Protein VI Mediates Membrane Disruption following Capsid Disassembly , 2005, Journal of Virology.
[19] A. Budkowska,et al. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. , 2009, The Journal of general virology.
[20] N. Lurain,et al. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). , 1995, Journal of immunology.
[21] P. Choyke,et al. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.
[22] G. Trugnan,et al. Rotavirus-Like Particles: A Novel Nanocarrier for the Gut , 2010, Journal of biomedicine & biotechnology.
[23] T. Tuschl,et al. Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy , 2005, Science.
[24] A. Cuconati,et al. Hepatitis B Virus , 2017, Methods in Molecular Biology.
[25] Wenhui Li,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.
[26] R. Hancock,et al. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.
[27] E. Wiertz,et al. Viral immune evasion: a masterpiece of evolution , 2002, Immunogenetics.
[28] R. Dwek,et al. Glycosylation and the immune system. , 2001, Science.
[29] E. Hildt,et al. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens , 2000, Gene Therapy.
[30] D. Carey,et al. Syndecans: multifunctional cell-surface co-receptors. , 1997, The Biochemical journal.
[31] N. Steinmetz,et al. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. , 2014, Virology.
[32] C. Cho,et al. Hybrid of baculovirus and galactosylated PEI for efficient gene carrier. , 2009, Virology.
[33] H. Yagi,et al. Human Liver-Specific Nanocarrier in a Novel Mouse Xenograft Model Bearing Noncancerous Human Liver Tissue , 2010, European Surgical Research.
[34] S. Roche,et al. Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G , 2007, Science.
[35] J. Schiller,et al. A Membrane-Destabilizing Peptide in Capsid Protein L2 Is Required for Egress of Papillomavirus Genomes from Endosomes , 2006, Journal of Virology.
[36] David F. Smith,et al. Human Parainfluenza Viruses hPIV1 and hPIV3 Bind Oligosaccharides with α2-3-Linked Sialic Acids That Are Distinct from Those Bound by H5 Avian Influenza Virus Hemagglutinin , 2007, Journal of Virology.
[37] B. Rothen‐Rutishauser,et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. , 2002, Cancer research.
[38] W. Oyen,et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.
[39] K. Zatloukal,et al. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[40] Shiroh Futaki,et al. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[41] A. Ullrich,et al. Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.
[42] E. Wagner,et al. Rhinovirus-mediated endosomal release of transfection complexes , 1995, Journal of virology.
[43] T. Friedmann,et al. Enhanced Gene Transfer with Fusogenic Liposomes Containing Vesicular Stomatitis Virus G Glycoprotein , 1998, Journal of Virology.
[44] R. Iozzo. Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.
[45] H. Müller-Eberhard,et al. Molecular organization and function of the complement system. , 1988, Annual review of biochemistry.
[46] T. Heath,et al. FORMATION OF VIROSOMES FROM INFLUENZA SUBUNITS AND LIPOSOMES , 1975, The Lancet.
[47] E. Blanchard,et al. Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis , 2006, Journal of Virology.
[48] L. Yang,et al. Barrel-stave model or toroidal model? A case study on melittin pores. , 2001, Biophysical journal.
[49] A. Kondo,et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes , 2003, Nature Biotechnology.
[50] R. Ritchie,et al. Bioinspired structural materials. , 2014, Nature Materials.
[51] Charles M. Rice,et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.
[52] K. Wooley,et al. Strategies Toward Well-Defined Polymer Nanoparticles Inspired by Nature: Chemistry versus Versatility. , 2012, Journal of polymer science. Part A, Polymer chemistry.
[53] B. Yélamos,et al. Study of the putative fusion regions of the preS domain of hepatitis B virus. , 2015, Biochimica et biophysica acta.
[54] E. Choi,et al. Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. , 2011, Protein expression and purification.
[55] J. Galama,et al. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release , 1997, The EMBO journal.
[56] A. Zuckerman,et al. Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.
[57] J. Wixon,et al. Gene therapy clinical trials worldwide 1989–2004—an overview , 2004, The journal of gene medicine.
[58] C. Guguen-Guillouzo,et al. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. , 1995, Virology.
[59] G. Kotwal. Poxviral mimicry of complement and chemokine system components: what's the end game? , 2000, Immunology today.
[60] Gustaf E. Rydell,et al. Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. , 2017, Virology.
[61] G. Whittaker,et al. Fusion of Enveloped Viruses in Endosomes , 2016, Traffic.
[62] Charles M. Rice,et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.
[63] Ernst Wagner,et al. Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems , 2006, The AAPS Journal.
[64] Ari Helenius,et al. Virus entry by endocytosis. , 2010, Annual review of biochemistry.
[65] Trevor Douglas,et al. Viruses: Making Friends with Old Foes , 2006, Science.
[66] S. Dowdy. Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.
[67] Jesse V Jokerst,et al. Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.
[68] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[69] F. Chisari,et al. To kill or to cure: options in host defense against viral infection. , 1996, Current opinion in immunology.
[70] G. Nybakken,et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H , 2006, Proceedings of the National Academy of Sciences.
[71] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[72] Xiaoyang Xu,et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.
[73] Kazunori Kataoka,et al. Progress of drug-loaded polymeric micelles into clinical studies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[74] M. Dierich,et al. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) , 1996, The Journal of experimental medicine.
[75] J. Skehel,et al. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.
[76] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[77] V. Venditto,et al. Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.
[78] Wim E. Hennink,et al. Artificial viruses: a nanotechnological approach to gene delivery , 2006, Nature Reviews Drug Discovery.
[79] U. Greber,et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake , 2002, The Journal of cell biology.
[80] Masumi Iijima,et al. Intracellular trafficking of bio-nanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[81] J. Atabekov,et al. Thermal transition of native tobacco mosaic virus and RNA-free viral proteins into spherical nanoparticles. , 2011, The Journal of general virology.
[82] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[83] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[84] A. Kidd,et al. Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor , 2000, Journal of Virology.
[85] Junichi Nakai,et al. Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells , 2008 .
[86] W. Carman,et al. Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. , 1992, The Journal of clinical investigation.
[87] H. Geuze,et al. Human Macrophages Accumulate HIV‐1 Particles in MHC II Compartments , 2002, Traffic.
[88] C. Schwegmann-Wessels,et al. Sialic acids as receptor determinants for coronaviruses , 2006, Glycoconjugate Journal.
[89] J. Behr,et al. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway , 1999, Gene Therapy.
[90] H. Ploegh. Viral strategies of immune evasion. , 1998, Science.
[91] T. Geijtenbeek,et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1 , 2007, Proceedings of the National Academy of Sciences.
[92] Samir Mitragotri,et al. Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[93] L. Lopalco,et al. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. , 1995, AIDS research and human retroviruses.
[94] Dong Chen,et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.
[95] M. Zerial,et al. rab5 controls early endosome fusion in vitro , 1991, Cell.
[96] A. Helenius,et al. On the entry of semliki forest virus into BHK-21 cells , 1980, The Journal of cell biology.
[97] In‐San Kim,et al. Bioengineered protein-based nanocage for drug delivery. , 2016, Advanced drug delivery reviews.
[98] T. Graule,et al. Isoelectric points of viruses , 2009, Journal of applied microbiology.
[99] Joohee Jung,et al. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[100] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[101] T. Ishida,et al. Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats , 2010, Pharmaceutics.
[102] R. Bartenschlager,et al. Replication of hepatitis C virus. , 2000, The Journal of general virology.
[103] R. Wagner,et al. Virus-like particles—universal molecular toolboxes , 2007, Current Opinion in Biotechnology.
[104] A. Helenius,et al. Fusion of Semliki forest virus with the plasma membrane can be induced by low pH , 1980, The Journal of cell biology.
[105] V. Torchilin,et al. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[106] Sarah Seifert,et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.
[107] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[108] Y Ikada,et al. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. , 1988, Biomaterials.
[109] R. Nolte,et al. Temperature‐Switchable Assembly of Supramolecular Virus–Polymer Complexes , 2011 .
[110] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[111] Samir Mitragotri,et al. Role of Particle Size in Phagocytosis of Polymeric Microspheres , 2008, Pharmaceutical Research.
[112] K. P. Murphy,et al. Janeway's immunobiology , 2007 .
[113] Charles M. Rice,et al. The ins and outs of hepatitis C virus entry and assembly , 2013, Nature Reviews Microbiology.
[114] Zhenghong Yuan,et al. Gene delivery into hepatocytes with the preS/liposome/DNA system , 2008, Biotechnology journal.
[115] P. Cicuta,et al. Phagocytosis dynamics depends on target shape. , 2013, Biophysical journal.
[116] E. Damonte,et al. Functional entry of dengue virus into Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis. , 2008, The Journal of general virology.
[117] J. Wilschut,et al. Virosome-mediated delivery of protein antigens to dendritic cells. , 2002, Vaccine.
[118] M. Mano,et al. Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and Generation of Delivery Systems , 2010, Pharmaceuticals.
[119] R. Bartenschlager,et al. A Slow Maturation Process Renders Hepatitis B Virus Infectious. , 2016, Cell host & microbe.
[120] Arezou A Ghazani,et al. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.
[121] M. Hashizume,et al. Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery. , 2015, Protein expression and purification.
[122] N. Pochet,et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses , 2016, Hepatology.
[123] C. Sureau,et al. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A‐determinant , 2013, Hepatology.
[124] E. Choi,et al. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[125] M. Imamura,et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor , 2011, Nature Medicine.
[126] R. Cortese,et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.
[127] M. Carroll,et al. The complement system in regulation of adaptive immunity , 2004, Nature Immunology.
[128] Tomoyuki Nishikawa,et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[129] J. Navaza,et al. The Fusion Glycoprotein Shell of Semliki Forest Virus An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH , 2001, Cell.
[130] P. Hilgard,et al. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes , 2000, Hepatology.
[131] K. Kirkegaard,et al. Remodeling the Endoplasmic Reticulum by Poliovirus Infection and by Individual Viral Proteins: an Autophagy-Like Origin for Virus-Induced Vesicles , 2000, Journal of Virology.
[132] M. Marsh,et al. The cell biology of receptor-mediated virus entry , 2011, The Journal of cell biology.
[133] E. Choi,et al. Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy , 2015, International journal of nanomedicine.
[134] C. Malboeuf,et al. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. , 2007, Vaccine.
[135] A. Alcamí,et al. Viral mechanisms of immune evasion , 2000, Immunology Today.
[136] Duane E. Prasuhn,et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[137] D. Metzger,et al. Fc Receptor-Mediated Phagocytosis Makes a Significant Contribution to Clearance of Influenza Virus Infections1 , 2001, The Journal of Immunology.
[138] Robert G Parton,et al. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. , 2005, Biochimica et biophysica acta.
[139] Y. Kaneda,et al. Virosomes: evolution of the liposome as a targeted drug delivery system. , 2000, Advanced drug delivery reviews.
[140] S. Kuroda,et al. Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein. , 1992, Journal of biotechnology.
[141] R. Bartenschlager,et al. Strategies to inhibit entry of HBV and HDV into hepatocytes. , 2014, Gastroenterology.
[142] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[143] W. DeGrado,et al. Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2. , 1987, The Journal of biological chemistry.
[144] Hamidreza Ghandehari,et al. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[145] Xuanmiao Zhang,et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. , 2014, Biomaterials.
[146] S. Cusack,et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.
[147] S. Kuroda,et al. Cellular uptake of hepatitis B virus envelope L particles is independent of sodium taurocholate cotransporting polypeptide, but dependent on heparan sulfate proteoglycan. , 2016, Virology.
[148] Lisa Brannon-Peppas,et al. Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.
[149] Pratip K. Chattopadhyay,et al. The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection , 2009, Journal of Virology.
[150] Benjamin J. Briggs,et al. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. , 2005, Virology.
[151] J. Esko,et al. Heparan sulfate proteoglycans. , 2011, Cold Spring Harbor perspectives in biology.
[152] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[153] Dominic J. Glover,et al. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[154] F. Chisari,et al. Stealth and Cunning: Hepatitis B and Hepatitis C Viruses , 2005, Journal of Virology.
[155] S. Urban,et al. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. , 2007, Hepatology.